Galantamine hydrobromide is a selective, reversible, competitive acetylcholinesterase (AChE) inhibitor. It is a potent allosteric potentiating ligand (APL) of human α4β2, α3β4, and α6β4 nicotinic acetylcholine receptors (nAChRs).
Galantamine hydrobromide is primarily used in the treatment of Alzheimer’s disease (AD) due to its ability to enhance cholinergic function by increasing acetylcholine levels in the brain. It is derived from natural sources such as the bulbs and flowers of Galanthus species and can also be synthesized.
Galantamine hydrobromide has been shown to inhibit amyloid-beta (Aβ) aggregation and protect against Aβ-induced toxicity in neuronal cells. It is available in both prescription and over-the-counter forms and is known for its cognitive-enhancing and neuroprotective effects.
The above informationis displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.
Sources:
https://en.wikipedia.org/wiki/Galantamine
https://psychonautwiki.org/wiki/Galantamine
https://www.medchemexpress.com/Galanthamine-hydrobromide.html
https://www.medkoo.com/products/8143
https://go.drugbank.com/salts/DBSALT000316
